Lights0rt

Thanks for this! I have a couple of questions.

1. Since the deal was announced, the share price of SRNG has been sitting below NAV. I believe this has to due with the valuation given at this point in time rather than the target company. We have seen reports of 90% of shares being redeemed when this happens. Is this being considered? Also, would you be open to the possibility to reconsider the valuation set forth? Many believe a lot of the growth in the short term has been priced in at the current valuation.
2. Since you open up your foundry to anybody, is it possible for you to develop strains for two directly competing companies? For example: I know that you work closely with Motif, but if another plant-based food company comes along and says "I can do what Motif is doing, but better" can they come to you for their strain development? How would that work?

Thanks, I'll see what the market prices DNA after the merger and then buy in for the long term hold. That is a good point about SEC and surely had an affect on the SPAC market, however, some SPACs have been trading above NAV because they are favorable deal terms for retail investors. Some examples are RICE, PSAC, and MUDS. I assume the number of redemptions is a nonfactor in finalizing the merger with SRNG?